Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-03-25 | Dr. Tannenbaum was appointed to the Board in March 2022. No committee assignments have been determined as of the date of this proxy statement. |
| 2023-04-11 | Dr. Tannenbaum is currently a member of the Compensation Committee. Total compensation $375,933. |
| 2024-04-05 | Renee P. Tannenbaum, Pharm.D., 72, has served as a director since March 2022. Dr. Tannenbaum is currently a member of the Board's Compensation Committee and a member of the Board’s Nominating and Corporate Governance Committee. The following table sets forth certain information with respect to the compensation paid or awarded by the Company to its non-employee directors who served for some portion or all of the fiscal year ended December 31, 2023. Renee Tannenbaum received total compensation of $392,366. |
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-28 | Dr. Tannenbaum currently serves as Vice President of Global Partnering at Halozyme, Inc... The Board believes that Dr. Tannenbaum’s extensive experience in the biopharmaceutical industry... provides her with the qualifications and skills to serve as a director. |
| 2022-04-14 | Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut. The Board believes that Dr. Tannenbaum’s extensive experience in the biopharmaceutical industry... provides her with the qualifications and skills to serve as a director. |
| 2023-04-27 | Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut. |
| 2024-04-25 | Dr. Tannenbaum received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, her MBA from Temple University, and her Bachelor of Science degree in Pharmacy from the University of Connecticut. The Board believes that Dr. Tannenbaum’s extensive experience in the biopharmaceutical industry, including providing strong executive leadership to numerous biopharmaceutical companies provides her with the qualifications and skills to serve as a director. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22